ENTYVIO®
ENTYVIO® (Vedolizumab) is an anti-inflammatory drug used to treat Inflammatory Bowel Diseases.
ENTYVIO® is manufactured by Takeda.
Administration and Dosage:
Administration of ENTYVIO® follows an induction regimen of 3 intravenous infusions at 0, 2, and 6 weeks followed by a maintenance infusion, once every 8 weeks.
Indication:
ENTYVIO® is indicated to treat:
- Crohn’s Disease
- Ulcerative Colitis
Common Side Effects:
The more common side effects of ENTYVIO® include infusion-related and serious allergic reactions, infections, Progressive Multifocal Leukoencephalopathy (PML), and liver problems.
More information:
Please read the full Prescribing Information and Medication Guide for ENTYVIO® and discuss any questions you have with your doctor.
HAVE QUESTIONS?
We are happy to help!
